ETON has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ETON has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Eton Pharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2024 was -23.81%.
Eton Pharmaceuticals's Revenue per Share for the three months ended in Jun. 2024 was $0.35.
The historical data trend for Eton Pharmaceuticals's YoY Rev. per Sh. Growth can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eton Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
YoY Rev. per Sh. Growth | Get a 7-Day Free Trial | - | -96.30 | 43,200.00 | -2.42 | 46.04 |
Eton Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
YoY Rev. per Sh. Growth | Get a 7-Day Free Trial | 57.68 | 114.96 | -15.22 | 48.56 | -23.81 |
YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.
Eton Pharmaceuticals's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:
YoY Rev. per Sh. Growth (A: Dec. 2023 ) | |||||
= | (Revenue per Share (A: Dec. 2023 ) | - | Revenue per Share (A: Dec. 2022 )) | / | | Revenue per Share (A: Dec. 2022 ) | |
= | (1.234 | - | 0.845) | / | | 0.845 | |
= | 46.04 % |
Eton Pharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2024 is calculated as:
YoY Rev. per Sh. Growth (Q: Jun. 2024 ) | |||||
= | (Revenue per Share (Q: Jun. 2024 ) | - | Revenue per Share (Q: Jun. 2023 )) | / | | Revenue per Share (Q: Jun. 2023 )) | |
= | (0.352 | - | 0.462) | / | | 0.462 | |
= | -23.81 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Eton Pharmaceuticals's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.
Opaleye Management Inc. | 10 percent owner | ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108 |
David Krempa | officer: Chief Business Officer | 29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010 |
Sean Brynjelsen | director, officer: President & CEO | C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010 |
James R. Gruber | officer: Chief Financial Officer | 618 AMES STREET, LIBERTYVILLE IL 60048 |
William Wilson Troutman | officer: CFO, Treasurer & Secretary | 21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010 |
Imprimis Pharmaceuticals, Inc. | 10 percent owner | 102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215 |
Jennifer Mckie Adams | director | 5410 TENNESSEE AVE, NASHVILLE TN 37209 |
Charles J Casamento | director | 99 BELBROOK WAY, ATHERTON CA 94027 |
Norbert G Riedel | director | BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015 |
Mark L Baum | director | C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130 |
Paul V Maier | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By GlobeNewswire • 07-30-2024
By GuruFocus Research • 03-14-2024
By Marketwired • 08-22-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 10-30-2023
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 03-15-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.